AAP
ACOR

Ardsley Advisory Partners’s Acorda Therapeutics ACOR Stock Holding History

Ardsley Advisory Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,229
Closed -$5M – 246
2014
Q3 		$5M Buy
+1,229
New +$4.61M 0.66% 39

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Ardsley Advisory Partners's ACOR Position: Q4 2014 in Review

Ardsley Advisory Partners sold out of Acorda Therapeutics (ACOR) in Q4 2014, closing a stake of 1,229 shares — an estimated $5M sold.

Ardsley Advisory Partners first reported a position in ACOR in Q3 2014 and held it in 1 quarter. The position peaked at $5M in Q3 2014. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2014.

  • Ardsley Advisory Partners reported no remaining Acorda Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Ardsley Advisory Partners sold 1,229 Acorda Therapeutics shares in Q4 2014, an estimated $5M.
  • Ardsley Advisory Partners first reported a position in Acorda Therapeutics in Q3 2014 and held it in 1 quarter.
  • Ardsley Advisory Partners's Acorda Therapeutics position peaked at $5M in Q3 2014.
  • 179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2014.

Based on Ardsley Advisory Partners's 13F filing for Q4 2014, filed 17 Feb 2015.